A pilot study of intensive short‐time continuous renal replacement therapy to substitute maintenance hemodialysis during transitional period of COVID‐19

Abstract

AbstractIntroductionThere is a lack of perfect solutions for maintenance hemodialysis (MHD) in patients with a high transmission risk of SARS‐CoV‐2.MethodsMHD patients with a high risk of SARS‐CoV‐2 transmission from April 1 to June 30, 2022, were recruited. We performed 4‐h continuous renal replacement therapy with Prismaflex dialysis machine and ST100 suite using continuous venovenous hemodiafiltration (CVVHDF) mode with a fluid exchange volume of 8000 mL/h.ResultsForty‐five MHD patients were included with a median dialysis age of 91 months. Overall spKt/V reached 0.96 ± 0.19. Urea reduction ratio was 50.29 ± 7.60% with the ultrafiltration of 2.18 ± 0.79 kg. Dry weight was significantly inversely correlated with spKt/V (R = −0.563, p < 0.001). Female gender was a significant positive factor of spKt/V. Preheating of replacement solution using an incubator solved the complication of shivering in most patients.ConclusionIntensive short‐time CVVHDF may be considered as an alternative for routine MHD during COVID‐19 transitional period.